阈值下微脉冲激光在中心性浆液性脉络膜视网膜病变中的作用机制  

Research progress on the mechanism of subthreshold micropulse laser photocoagulation in central serous chorioretinopathy

作　　者：路雪 谢兵 Lu Xue;Xie Bing(Department of Ophthalmology,Affiliated Hospital of Zunyi Medical University,Zunyi 563000,Guizhou Province,China)

机构地区：[1]遵义医科大学附属医院眼科,贵州省遵义市563000

出　　处：《国际眼科杂志》2024年第5期749-752,共4页International Eye Science

摘　　要：中心性浆液性脉络膜视网膜病变(CSC)是发生在中青年患者中常见的黄斑病变,该病具有一定自限性,但治疗不及时也可致病情迁延、反复发作,进展为慢性CSC、继发视网膜色素上皮(RPE)萎缩、脉络膜新生血管等,最终导致中心视力不可逆性损害。阈值下微脉冲激光(SMLP)是一种短促重复的脉冲激光,它不同于具有损伤性治疗作用的传统激光,在达到有效治疗效果的基础上,不会对RPE细胞和光感受器造成损伤和热损伤。在光动力治疗(PDT)缺乏维替泊芬的情况下,因其有效性、安全性和可重复性,SMLP现已广泛应用于临床上CSC的治疗。本综述旨在阐述SMLP治疗CSC过程中涉及的效应细胞、细胞因子及作用机制,以期为SMLP在临床的推广和合理化应用提供更多理论依据。Central serous chorioretinopathy(CSC)is a common macular degeneration that primarily affects young patients.While the disease may resolve on its own to some extent,delayed or inadequate treatment can result in recurrence and progression to chronic CSC.This can lead to complications such as retinal pigment epithelium(RPE)atrophy and choroidal neovascularization,ultimately causing irreversible damage to central vision.Subthreshold micropulse laser photocoagulation(SMLP)is a type of laser therapy that differs from traditional lasers in that it does not cause damage or thermal injury to RPE cells and photoreceptors.SMLP has become widely used in clinical treatment of CSC due to its effectiveness,safety,and reproducibility,particularly in cases where verteporfin is not available in photodynamic therapy(PDT).The purpose of this review is to explain the mechanism of SMLP in CSC and summarize the effector cells,cytokines,and mechanisms of action involved in its treatment.This will provide a theoretical basis for promoting and rationalizing the use of SMLP in clinical practice.

关 键 词：中心性浆液性脉络膜视网膜病变 阈值下微脉冲激光 视网膜色素上皮 脉络膜毛细血管内皮细胞 作用机制 

分 类 号：R774.1[医药卫生—眼科]